Aytu BioPharma Inc. (NASDAQ:AYTU) Receives $9.83 Consensus Price Target from Analysts

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have earned an average rating of “Hold” from the five research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $9.8333.

AYTU has been the subject of a number of research analyst reports. Ascendiant Capital Markets boosted their price target on Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a report on Thursday, June 11th. Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a report on Wednesday, April 8th.

Hedge Funds Weigh In On Aytu BioPharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Persistent Asset Partners Ltd increased its holdings in Aytu BioPharma by 27.2% in the 4th quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock worth $206,000 after purchasing an additional 16,963 shares in the last quarter. Two Sigma Investments LP increased its holdings in Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after purchasing an additional 33,701 shares in the last quarter. DRW Securities LLC acquired a new position in Aytu BioPharma in the 4th quarter worth about $76,000. XTX Topco Ltd acquired a new position in Aytu BioPharma in the 4th quarter worth about $67,000. Finally, Dimensional Fund Advisors LP acquired a new position in Aytu BioPharma in the 3rd quarter worth about $58,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

Aytu BioPharma Price Performance

Aytu BioPharma stock opened at $2.17 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.00 and a current ratio of 1.12. Aytu BioPharma has a 52 week low of $1.65 and a 52 week high of $3.07. The stock has a market capitalization of $23.28 million, a P/E ratio of -0.47 and a beta of 0.24. The stock has a fifty day moving average of $2.31 and a 200-day moving average of $2.46.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%.The business had revenue of $12.41 million for the quarter, compared to analyst estimates of $12.05 million. On average, sell-side analysts expect that Aytu BioPharma will post -0.73 earnings per share for the current fiscal year.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.